Fastrack · Blood pressure medication recalled nationwide under FDA alert.

Inventia Healthcare Limited has recalled more than 25,000 bottles of chlorthalidone tablets nationwide. The drug failed to dissolve at the correct speed, which can affect how the active ingredient is absorbed.

11,460 bottles were recalled in an initial action on June 5.
13,567 additional bottles were recalled in a second action on Sept. 3.
Affected tablets are 25 mg, sold in 100- and 1,000-count bottles, expiring April 2027.
Batch codes RISA24001, RISB24002, and RISA24002 are covered by the recall.

Why it matters: Chlorthalidone is a diuretic that lowers blood pressure by increasing urine flow and reducing water and salt in the body. A dissolution failure means patients may not receive the full intended dose.

Class II status means adverse health consequences, if any, are likely temporary or reversible.
The FDA warns that stopping a recalled medication without guidance can sometimes be more harmful than continuing it.

How 6 sources split on this story

Source landscape

Factuality

High

Mixed

Low

Strong LeftLeftLean LeftCenterLean RightRightStrong Right

Political Bias

Coverage by lean% of 6 sources

6 sources · 6 articles · 100% Center coverage

Center coverage, 6 sources: The center presents the recall as a straightforward consumer safety notice, emphasizing FDA guidance and practical steps for patients.

USA Today10hBlood pressure medication recalled nationwide. See affected drug abcabc27 (WHTM)11hBlood pressure medication recalled nationwide under FDA's Class II risk level

The Hill11hBlood pressure medication recalled nationwide under FDA’s Class II risk level WNCWFLA News Channel 811hBlood pressure medication recalled nationwide under FDA's Class II risk level WYWKBN Youngstown11hBlood pressure medication recalled nationwide under FDA's Class II risk level WSWSAV Savannah11hBlood pressure medication recalled nationwide under FDA's Class II risk level

What’s next: Patients who have affected bottles should consult a doctor or pharmacist before stopping the medication.

The FDA advises continuing Class II recalled medications unless the recalling company instructs otherwise.
Has Inventia Healthcare identified the manufacturing root cause of the dissolution failure?
How many patients received the affected batches before the recalls were issued?